Company Description
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide.
The company operates through two segments, Protein Sciences, and Diagnostics and Genomics.
The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.
This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids.
The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications.
It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands.
The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014.
Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Country | United States |
IPO Date | Feb 9, 1989 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 3,100 |
CEO | Kim Kelderman |
Contact Details
Address: 614 McKinley Place N.E. Minneapolis, Minnesota United States | |
Website | https://www.bio-techne.com |
Stock Details
Ticker Symbol | TECH |
Exchange | NASDAQ |
Fiscal Year | July - June |
Reporting Currency | USD |
CIK Code | 0000842023 |
CUSIP Number | 09073M104 |
ISIN Number | US09073M1045 |
Employer ID | 41-1427402 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Kim Kelderman | Chief Executive Officer, President & Director |
Dr. Gary J. Latham Ph.D. | Vice President & Chief Technology Officer |
James T. Hippel CPA | Executive Vice President of Finance & Chief Financial Officer |
Cheryl Bethune | Senior Vice President & Chief Human Resources Officer |
David Clair C.F.A. | Senior Director of Investor Relations & Corporate Development |
Dr. Matthew F. McManus M.D., MBA, Ph.D. | President of Diagnostics & Genomics |
Gerry Andros | Vice President of Sales and Marketing |
Martin Wirtz | Senior Vice President of Strategy & Corporate Development |
Shane Bohnen | Senior Vice President, General Counsel, Corporate Secretary & Chief Sustainability Officer |
William A. Geist | President of Protein Sciences Segment |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
Nov 08, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 05, 2024 | 4 | Filing |
Nov 05, 2024 | 4 | Filing |
Nov 05, 2024 | 4 | Filing |
Nov 05, 2024 | 8-K | Current Report |
Nov 05, 2024 | 10-Q | Quarterly Report |
Oct 30, 2024 | 8-K | Current Report |
Oct 28, 2024 | 4 | Filing |
Oct 28, 2024 | 4 | Filing |